168 related articles for article (PubMed ID: 38409276)
1. Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck.
Sanz-Garcia E; Zou J; Avery L; Spreafico A; Waldron J; Goldstein D; Hansen A; Cho BCJ; de Almeida J; Hope A; Hosni A; Hahn E; Perez-Ordonez B; Zhao Z; Smith C; Zheng Y; Singaravelan N; Bratman SV; Siu LL
Cell Death Differ; 2024 Apr; 31(4):460-468. PubMed ID: 38409276
[TBL] [Abstract][Full Text] [Related]
2. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
Burgener JM; Zou J; Zhao Z; Zheng Y; Shen SY; Huang SH; Keshavarzi S; Xu W; Liu FF; Liu G; Waldron JN; Weinreb I; Spreafico A; Siu LL; de Almeida JR; Goldstein DP; Hoffman MM; De Carvalho DD; Bratman SV
Clin Cancer Res; 2021 Aug; 27(15):4230-4244. PubMed ID: 34158359
[TBL] [Abstract][Full Text] [Related]
4. Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma.
Kogo R; Manako T; Iwaya T; Nishizuka S; Hiraki H; Sasaki Y; Idogawa M; Tokino T; Koide A; Komune N; Yasumatsu R; Nakagawa T
Cancer Med; 2022 Nov; 11(21):3960-3968. PubMed ID: 35352507
[TBL] [Abstract][Full Text] [Related]
5. Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer.
Han K; Zou J; Zhao Z; Baskurt Z; Zheng Y; Barnes E; Croke J; Ferguson SE; Fyles A; Gien L; Gladwish A; Lecavalier-Barsoum M; Lheureux S; Lukovic J; Mackay H; Marchand EL; Metser U; Milosevic M; Taggar AS; Bratman SV; Leung E
J Clin Oncol; 2024 Feb; 42(4):431-440. PubMed ID: 37972346
[TBL] [Abstract][Full Text] [Related]
6. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma.
Flach S; Howarth K; Hackinger S; Pipinikas C; Ellis P; McLay K; Marsico G; Forshew T; Walz C; Reichel CA; Gires O; Canis M; Baumeister P
Br J Cancer; 2022 May; 126(8):1186-1195. PubMed ID: 35132238
[TBL] [Abstract][Full Text] [Related]
7. ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach.
Nielsen LR; Stensgaard S; Meldgaard P; Sorensen BS
Cancer Treat Res Commun; 2024; 39():100802. PubMed ID: 38428066
[TBL] [Abstract][Full Text] [Related]
8. Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma.
Chikuie N; Urabe Y; Ueda T; Hamamoto T; Taruya T; Kono T; Yumii K; Takeno S
Sci Rep; 2022 Jun; 12(1):9316. PubMed ID: 35661138
[TBL] [Abstract][Full Text] [Related]
9. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK
Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374
[TBL] [Abstract][Full Text] [Related]
10. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy.
Hilke FJ; Muyas F; Admard J; Kootz B; Nann D; Welz S; Rieß O; Zips D; Ossowski S; Schroeder C; Clasen K
Radiother Oncol; 2020 Oct; 151():182-189. PubMed ID: 32687856
[TBL] [Abstract][Full Text] [Related]
12. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
Parikh AR; Van Seventer EE; Siravegna G; Hartwig AV; Jaimovich A; He Y; Kanter K; Fish MG; Fosbenner KD; Miao B; Phillips S; Carmichael JH; Sharma N; Jarnagin J; Baiev I; Shah YS; Fetter IJ; Shahzade HA; Allen JN; Blaszkowsky LS; Clark JW; Dubois JS; Franses JW; Giantonio BJ; Goyal L; Klempner SJ; Nipp RD; Roeland EJ; Ryan DP; Weekes CD; Wo JY; Hong TS; Bordeianou L; Ferrone CR; Qadan M; Kunitake H; Berger D; Ricciardi R; Cusack JC; Raymond VM; Talasaz A; Boland GM; Corcoran RB
Clin Cancer Res; 2021 Oct; 27(20):5586-5594. PubMed ID: 33926918
[TBL] [Abstract][Full Text] [Related]
13. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
15. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients.
Taylor K; Zou J; Magalhaes M; Oliva M; Spreafico A; Hansen AR; McDade SS; Coyle VM; Lawler M; Elimova E; Bratman SV; Siu LL
Eur J Cancer; 2023 Jul; 188():29-38. PubMed ID: 37182343
[TBL] [Abstract][Full Text] [Related]
17. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
[TBL] [Abstract][Full Text] [Related]
18. Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer.
Chera BS; Kumar S; Shen C; Amdur R; Dagan R; Green R; Goldman E; Weiss J; Grilley-Olson J; Patel S; Zanation A; Hackman T; Blumberg J; Patel S; Thorp B; Weissler M; Yarbrough W; Sheets N; Mendenhall W; Tan XM; Gupta GP
J Clin Oncol; 2020 Apr; 38(10):1050-1058. PubMed ID: 32017652
[TBL] [Abstract][Full Text] [Related]
19. HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA.
Leung E; Han K; Zou J; Zhao Z; Zheng Y; Wang TT; Rostami A; Siu LL; Pugh TJ; Bratman SV
Clin Cancer Res; 2021 Nov; 27(21):5857-5868. PubMed ID: 34580115
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and Impact of HPV-Associated p16 Expression on Head and Neck Squamous Cell Carcinoma in Thai Patients.
Jiarpinitnun C; Larbcharoensub N; Pattaranutaporn P; Chureemas T; Juengsamarn J; Trachu N; Lukerak S; Chansriwong P; Ngamphaiboon N
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1679-1687. PubMed ID: 32592364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
